Content area

|
|

Kvalme og opkastning induceret af medicinsk kræftbehandling

Forfatter(e)
Peter Clausager Petersen1, Christina Ruhlmann2 & Jørn Herrstedt3, 4
1) Onkologisk Klinik, Rigshospitalet 2) Onkologisk Afdeling, Odense Universitetshospital 3) Klinisk Onkologisk Afdeling, Sjællands Universitetshospital, Roskilde 4) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet

Ugeskr Læger 2019;181:V02190115
Reference: 
Ugeskr Læger 2019;181:V02190115

Peter Clausager Petersen, Christina Ruhlmann & Jørn Herrstedt:

Nausea and vomiting induced by antineoplastic therapy

Ugeskr Læger 2019;181:V02190115

Nausea and vomiting are a persistent burden on cancer patients undergoing antineoplastic therapy, and adherence to guideline-specific prophylactic therapy is essential to minimise the risk. Nausea is more challenging to prevent than vomiting. This review summarises the choices of relevant drugs. Olanzapine is effective against nausea, but sedation can be a problem. There seems to be no major differences in effect or tolerability between different serotonin receptor antagonists and different neurokinin receptor antagonists. Consequently, the choice of drug should be based on price, risk of interactions and simple administration.

Du skal være logget ind for at læse denne artikel
Log ind

Right side